Associations - PALB2 mutation

PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Urothelial Cancer Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Endometrial Cancer Endometrial Cancer	rucaparib + E 3810 Sensitive: C4 – Case Studies
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: D – Preclinical